Abstract
AbstractUnique dosing strategy, outcome goals unveil possible alcohol treatment with nalmefeneRejection of Probuphine by FDA: Adequate dosing a key concernSertraline‐duloxetine combination may be linked to gynecomastiaVarenicline outperforms in smoking cessation, with few adverse eventsMethylphenidate appears effective for apathy in Alzheimer'sHaloperidol has faster onset vs. atypicalsHigh‐dose D‐cycloserine promising for treatment‐resistant depressionLevomilnacipran SR effective for major depressive disorder5‐HT1A partial agonists as adjunctive therapy for schizophreniaAntipsychotic augmentation for treatment‐resistant OCDTropisetron added to risperidone for schizophreniaApprovals
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
